Schonfeld Strategic Advisors LLC Halozyme Therapeutics, Inc. Transaction History

Schonfeld Strategic Advisors LLC

$14.6 Billion
Q2 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 26,394 shares of HALO stock, worth $1.36 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

26,394

Holding current value

$1.36 Million

% of portfolio

0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $997,957 - $1.38 Million	26,394 New	26,394 $1.38 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $931,260 - $1.18 Million	27,949 Added 426.51%	34,502 $1.28 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $238,922 - $288,528	6,553 New	6,553 $250,000
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $9.95 Million - $16.9 Million	-302,807 Reduced 91.54%	27,993 $1.07 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $2.34 Million - $3.47 Million	-58,431 Reduced 15.01%	330,800 $18.8 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $3.68 Million - $4.95 Million	95,593 Added 32.55%	389,231 $15.4 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $3.43 Million - $4.44 Million	91,833 Added 45.51%	293,638 $12.9 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $512,702 - $658,479	16,037 Added 8.63%	201,805 $8.05 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $1.46 Million - $1.87 Million	45,768 Added 32.69%	185,768 $7.47 Million
Q3 2021 Nov 16, 2021	SELL	$38.47 - $46.42 $4.06 Million - $4.9 Million	-105,600 Reduced 43.0%	140,000 $5.7 Million
Q2 2021 Nov 16, 2021	SELL	$38.84 - $51.31 $664,164 - $877,401	-17,100 Reduced 6.51%	245,600 $11.2 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $3.47 Million - $4.58 Million	89,299 Added 51.5%	262,700 $11.9 Million
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $5.2 Million - $6.77 Million	131,663 Added 315.45%	173,401 $7.23 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $778,481 - $1.32 Million	-30,162 Reduced 41.95%	41,738 $1.78 Million
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $296,241 - $341,011	11,509 Added 19.06%	71,900 $2,000
Q2 2020 Aug 14, 2020	BUY	$16.25 - $26.81 $531,147 - $876,311	32,686 Added 117.98%	60,391 $1.62 Million
Q1 2020 May 15, 2020	BUY	$13.9 - $21.83 $385,099 - $604,800	27,705 New	27,705 $498,000
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $869,440 - $1.01 Million	-57,200 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$14.75 - $17.26 $1.76 Million - $2.06 Million	-119,376 Reduced 67.61%	57,200 $983,000
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $2.14 Million - $2.7 Million	153,576 Added 667.72%	176,576 $2.84 Million
Q4 2018 Feb 14, 2019	BUY	$13.33 - $18.66 $306,590 - $429,180	23,000 New	23,000 $336,000

Others Institutions Holding HALO

# of Institutions

498

Shares Held

123M

Call Options Held

208K

Put Options Held

77.1K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.18B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Halozyme Therapeutics, Inc. Transaction History